Compare LMB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | CAPR |
|---|---|---|
| Founded | 1901 | 2005 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2014 | 2011 |
| Metric | LMB | CAPR |
|---|---|---|
| Price | $81.08 | $33.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $130.00 | $41.38 |
| AVG Volume (30 Days) | 157.1K | ★ 1.1M |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $646,804,000.00 | $22,270,465.00 |
| Revenue This Year | $16.50 | N/A |
| Revenue Next Year | $4.76 | $17,308.50 |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $63.02 | $4.30 |
| 52 Week High | $154.04 | $40.37 |
| Indicator | LMB | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 72.07 |
| Support Level | $77.96 | $22.09 |
| Resistance Level | $85.30 | $40.37 |
| Average True Range (ATR) | 6.63 | 1.84 |
| MACD | -1.66 | 0.46 |
| Stochastic Oscillator | 11.78 | 71.58 |
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.